Phase III KEYNOTE-048 study of first-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma: Asia vs non-Asia subgroup analysis
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2019-11, Vol.30, p.ix97 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | ix97 |
| container_title | Annals of oncology |
| container_volume | 30 |
| creator | Ngamphaiboon, N. Tanaka, K. Hong, R.-L. Wan Ishak, W.Z. Yen, C.-J. Sriuranpong, V. Takahashi, S. Srimuninnimit, V. Yeh, S.-P. Oridate, N. Yang, M.-H. Nohata, N. Koh, Y. Roy, A. Gumuscu, B. Swaby, R. Tahara, M. |
| description | |
| doi_str_mv | 10.1093/annonc/mdz428 |
| format | Article |
| fullrecord | <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdz428</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1093_annonc_mdz428</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1218-2f57dd5ee9a0b13a4d6d6afcb49275c29cca4e8853b7cf5a8a3ecce442cc643a3</originalsourceid><addsrcrecordid>eNotkLtOw0AQRbcAiRAo6ecHTNa76xddFAWwiIAiFFTWeLxLDH6EHRsp-RS-lkCo7m3u0dUR4iqU16HM9Ay7ru9o1lZ7o9ITMZGZ0kESaXMmzpnfpZRxprKJ-H7eIFvI8xwelq-PT-tlIE0KPIzVDnoHrvY8BE3dWdjatvR9U-_HFktwvQdvafTedsOstQPygENNsLFYAXYVdJY-gD9HbPuRgWzTAKGnuutbvIE51whfDIebwV_nsXzz_bg9bLHZcc0X4tRhw_byP6fi5Xa5XtwHq6e7fDFfBRSqMA2Ui5KqiqzNUJahRlPFVYyOSpOpJCKVEaGxaRrpMiEXYYraElljFFFsNOqpCI5c8j2zt67Y-rpFvytCWfzKLI4yi6NM_QP_Im_Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Phase III KEYNOTE-048 study of first-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma: Asia vs non-Asia subgroup analysis</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Ngamphaiboon, N. ; Tanaka, K. ; Hong, R.-L. ; Wan Ishak, W.Z. ; Yen, C.-J. ; Sriuranpong, V. ; Takahashi, S. ; Srimuninnimit, V. ; Yeh, S.-P. ; Oridate, N. ; Yang, M.-H. ; Nohata, N. ; Koh, Y. ; Roy, A. ; Gumuscu, B. ; Swaby, R. ; Tahara, M.</creator><creatorcontrib>Ngamphaiboon, N. ; Tanaka, K. ; Hong, R.-L. ; Wan Ishak, W.Z. ; Yen, C.-J. ; Sriuranpong, V. ; Takahashi, S. ; Srimuninnimit, V. ; Yeh, S.-P. ; Oridate, N. ; Yang, M.-H. ; Nohata, N. ; Koh, Y. ; Roy, A. ; Gumuscu, B. ; Swaby, R. ; Tahara, M.</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>DOI: 10.1093/annonc/mdz428</identifier><language>eng</language><ispartof>Annals of oncology, 2019-11, Vol.30, p.ix97</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1218-2f57dd5ee9a0b13a4d6d6afcb49275c29cca4e8853b7cf5a8a3ecce442cc643a3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Ngamphaiboon, N.</creatorcontrib><creatorcontrib>Tanaka, K.</creatorcontrib><creatorcontrib>Hong, R.-L.</creatorcontrib><creatorcontrib>Wan Ishak, W.Z.</creatorcontrib><creatorcontrib>Yen, C.-J.</creatorcontrib><creatorcontrib>Sriuranpong, V.</creatorcontrib><creatorcontrib>Takahashi, S.</creatorcontrib><creatorcontrib>Srimuninnimit, V.</creatorcontrib><creatorcontrib>Yeh, S.-P.</creatorcontrib><creatorcontrib>Oridate, N.</creatorcontrib><creatorcontrib>Yang, M.-H.</creatorcontrib><creatorcontrib>Nohata, N.</creatorcontrib><creatorcontrib>Koh, Y.</creatorcontrib><creatorcontrib>Roy, A.</creatorcontrib><creatorcontrib>Gumuscu, B.</creatorcontrib><creatorcontrib>Swaby, R.</creatorcontrib><creatorcontrib>Tahara, M.</creatorcontrib><title>Phase III KEYNOTE-048 study of first-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma: Asia vs non-Asia subgroup analysis</title><title>Annals of oncology</title><issn>0923-7534</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNotkLtOw0AQRbcAiRAo6ecHTNa76xddFAWwiIAiFFTWeLxLDH6EHRsp-RS-lkCo7m3u0dUR4iqU16HM9Ay7ru9o1lZ7o9ITMZGZ0kESaXMmzpnfpZRxprKJ-H7eIFvI8xwelq-PT-tlIE0KPIzVDnoHrvY8BE3dWdjatvR9U-_HFktwvQdvafTedsOstQPygENNsLFYAXYVdJY-gD9HbPuRgWzTAKGnuutbvIE51whfDIebwV_nsXzz_bg9bLHZcc0X4tRhw_byP6fi5Xa5XtwHq6e7fDFfBRSqMA2Ui5KqiqzNUJahRlPFVYyOSpOpJCKVEaGxaRrpMiEXYYraElljFFFsNOqpCI5c8j2zt67Y-rpFvytCWfzKLI4yi6NM_QP_Im_Q</recordid><startdate>201911</startdate><enddate>201911</enddate><creator>Ngamphaiboon, N.</creator><creator>Tanaka, K.</creator><creator>Hong, R.-L.</creator><creator>Wan Ishak, W.Z.</creator><creator>Yen, C.-J.</creator><creator>Sriuranpong, V.</creator><creator>Takahashi, S.</creator><creator>Srimuninnimit, V.</creator><creator>Yeh, S.-P.</creator><creator>Oridate, N.</creator><creator>Yang, M.-H.</creator><creator>Nohata, N.</creator><creator>Koh, Y.</creator><creator>Roy, A.</creator><creator>Gumuscu, B.</creator><creator>Swaby, R.</creator><creator>Tahara, M.</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201911</creationdate><title>Phase III KEYNOTE-048 study of first-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma: Asia vs non-Asia subgroup analysis</title><author>Ngamphaiboon, N. ; Tanaka, K. ; Hong, R.-L. ; Wan Ishak, W.Z. ; Yen, C.-J. ; Sriuranpong, V. ; Takahashi, S. ; Srimuninnimit, V. ; Yeh, S.-P. ; Oridate, N. ; Yang, M.-H. ; Nohata, N. ; Koh, Y. ; Roy, A. ; Gumuscu, B. ; Swaby, R. ; Tahara, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1218-2f57dd5ee9a0b13a4d6d6afcb49275c29cca4e8853b7cf5a8a3ecce442cc643a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ngamphaiboon, N.</creatorcontrib><creatorcontrib>Tanaka, K.</creatorcontrib><creatorcontrib>Hong, R.-L.</creatorcontrib><creatorcontrib>Wan Ishak, W.Z.</creatorcontrib><creatorcontrib>Yen, C.-J.</creatorcontrib><creatorcontrib>Sriuranpong, V.</creatorcontrib><creatorcontrib>Takahashi, S.</creatorcontrib><creatorcontrib>Srimuninnimit, V.</creatorcontrib><creatorcontrib>Yeh, S.-P.</creatorcontrib><creatorcontrib>Oridate, N.</creatorcontrib><creatorcontrib>Yang, M.-H.</creatorcontrib><creatorcontrib>Nohata, N.</creatorcontrib><creatorcontrib>Koh, Y.</creatorcontrib><creatorcontrib>Roy, A.</creatorcontrib><creatorcontrib>Gumuscu, B.</creatorcontrib><creatorcontrib>Swaby, R.</creatorcontrib><creatorcontrib>Tahara, M.</creatorcontrib><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ngamphaiboon, N.</au><au>Tanaka, K.</au><au>Hong, R.-L.</au><au>Wan Ishak, W.Z.</au><au>Yen, C.-J.</au><au>Sriuranpong, V.</au><au>Takahashi, S.</au><au>Srimuninnimit, V.</au><au>Yeh, S.-P.</au><au>Oridate, N.</au><au>Yang, M.-H.</au><au>Nohata, N.</au><au>Koh, Y.</au><au>Roy, A.</au><au>Gumuscu, B.</au><au>Swaby, R.</au><au>Tahara, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phase III KEYNOTE-048 study of first-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma: Asia vs non-Asia subgroup analysis</atitle><jtitle>Annals of oncology</jtitle><date>2019-11</date><risdate>2019</risdate><volume>30</volume><spage>ix97</spage><pages>ix97-</pages><issn>0923-7534</issn><doi>10.1093/annonc/mdz428</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2019-11, Vol.30, p.ix97 |
| issn | 0923-7534 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_annonc_mdz428 |
| source | EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| title | Phase III KEYNOTE-048 study of first-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma: Asia vs non-Asia subgroup analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T07%3A15%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phase%20III%20KEYNOTE-048%20study%20of%20first-line%20pembrolizumab%20for%20recurrent/metastatic%20head%20and%20neck%20squamous%20cell%20carcinoma:%20Asia%20vs%20non-Asia%20subgroup%20analysis&rft.jtitle=Annals%20of%20oncology&rft.au=Ngamphaiboon,%20N.&rft.date=2019-11&rft.volume=30&rft.spage=ix97&rft.pages=ix97-&rft.issn=0923-7534&rft_id=info:doi/10.1093/annonc/mdz428&rft_dat=%3Ccrossref%3E10_1093_annonc_mdz428%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |